Cash & Equivalents
Regeneron Pharmaceuticals Cash & Equivalents decreased by 4.7% to $2.97B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.0%, from $3.09B to $2.97B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 7.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.08B | $3.44B | $2.89B | $3.36B | $3.41B | $3.50B | $3.11B | $3.93B | $1.95B | $2.16B | $2.73B | $2.61B | $1.93B | $2.01B | $2.49B | $3.09B | $2.02B | $2.51B | $3.12B | $2.97B |
| QoQ Change | — | +65.2% | -16.2% | +16.4% | +1.5% | +2.8% | -11.4% | +26.5% | -50.4% | +10.8% | +26.4% | -4.4% | -26.1% | +4.3% | +23.7% | +24.3% | -34.8% | +24.7% | +24.1% | -4.7% |
| YoY Change | — | — | — | — | +63.5% | +1.7% | +7.6% | +17.0% | -42.8% | -38.4% | -12.1% | -33.6% | -1.1% | -6.9% | -8.9% | +18.5% | +4.5% | +24.9% | +25.3% | -4.0% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's cash & equivalents?
- Regeneron Pharmaceuticals (REGN) reported cash & equivalents of $2.97B in Q1 2026.
- How has Regeneron Pharmaceuticals's cash & equivalents changed year-over-year?
- Regeneron Pharmaceuticals's cash & equivalents decreased by 4.0% year-over-year, from $3.09B to $2.97B.
- What is the long-term trend for Regeneron Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's cash & equivalents has grown at a 7.3% compound annual growth rate (CAGR), from $2.19B to $3.12B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.